Persongen Biotherapeutics (suzhou) Co., Ltd.

This study tests a new injection called UTAA07 for adults with CD7-positive blood cancers that have come back or not responded to treatment. The main goals are to check safety and find the best dose. Only 15 people will take part in this early-stage trial.

This early-phase trial is testing a new cell therapy called LV009 for people with certain blood cancers (lymphoma and leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goal is to c…

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or stopped responding to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection a…

This Phase 2 trial tests a single infusion of PA3-17, a CAR-T cell therapy that targets CD7 on cancer cells, in 100 adults with relapsed or refractory T-lymphoblastic leukemia or lymphoma. Participants receive the treatment after a short chemotherapy prep, and researchers will mo…